Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

• প্রধান লেখক: Thomas Bettuzzi (লেখক), Hervé Bachelez (লেখক), Marie Beylot-Barry (লেখক), Hugo Arlégui (লেখক), Carle Paul (লেখক), Manuelle Viguier (লেখক), Emmanuel Mahé (লেখক), Nathalie Beneton (লেখক), Denis Jullien (লেখক), Marie-Aleth Richard (লেখক), Pascal Joly (লেখক), Florence Tubach (লেখক), Alain Dupuy (লেখক), Emilie Sbidian (লেখক), Olivier Chosidow (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Medical Journals Sweden, 2022-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (...